PPARA and metabolic dysfunction-associated steatohepatitis: In the present study we analysed liver biopsies from 249 patients with a suspicion of MASH screened for inclusion in the NATIVE clinical trial,31 aiming at identifying clinical and histological features associated with LSECs capillarisation and its spatial distribution in MASLD, and at assessing whether LSEC changes in patients can regress following treatment with the pan-PPAR agonist lanifibranor.